NCT04091750 2026-03-03Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaGeorgetown UniversityPhase 2 Active not recruiting14 enrolled 9 charts
NCT05200143 2024-09-19Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaProvidence Health & ServicesPhase 2 Terminated4 enrolled 11 charts
NCT02036476 2023-05-09Cabozantinib in Recurrent/Metastatic Merkel Cell CarcinomaDana-Farber Cancer InstitutePhase 2 Terminated8 enrolled 7 charts